Be the first person to write a business review for Monogram Biosciences, Inc.

Myriad Genetics, Inc. company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics, Inc., a healthcare company, focuses on the development and marketing of novel molecular diagnostic products. It commercializes predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for assessing a woman's risk for breast and ovarian cancer; COLARIS molecular for assessing a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; and MELARIS, which assesses a persons risk of developing melanoma. It also offers OnDose, a personalized medicine product to measure a patient's exposure to 5-FU chemotherapy; PREZEON that assesses loss of PTEN function in cancer patients; and TheraGuide 5-FU assesses a person's risk of developing a toxic reaction to 5-FU-based chemotherapy.

Neogen Corporation was founded in 1981 and is based in Lansing, Michigan. Neogen Corporation (Neogen), together with its subsidiaries, develops, manufactures and markets a line of products dedicated to food and animal safety. The Company operates in two primary business areas: the food safety segment and the animal safety segment. The Company’s food safety segment consists primarily of diagnostic test kits and complementary products marketed by sales personnel in the North American, Mexico, the United Kingdom and other parts of Europe, and by distributors elsewhere to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed. Neogen’s animal safety segment is engaged in the development, manufacture and marketing of pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals and diagnostic products for the worldwide animal safety market. In May 4, 2009, Neogen acquired International Diagnostic Systems Corporation.

Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada. Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products include NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease. The company's products under development comprises NX-1207, which is in phase III trial for the treatment of enlarged prostate; NXC-4720, an antibacterial agent that is in laboratory trials for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat, and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans; and Statins, a class of commonly prescribed cholesterol lowering drugs to treat, prevent, or reduce the risk of Alzheimer's disease. It is also in the preclinical stage of developing therapeutic products for oncological indications; and has various diagnostic markers and technologies, including a patented platform for point-of-care testing.

Omega Diagnostics Group PLC is a United Kingdom-based holding company. The Company, along with its subsidiaries, is principally engaged in the manufacture, development and distribution of medical diagnostic products. The Company sells a range of products, primarily in the immunoassay, in-vitro diagnostics (IVD) market, through a distribution network in over 100 countries. The Company operates in a niche market in supplying tests for specific infectious diseases, autoimmune disease and food tolerance. The Company subsidiaries include Investment in Omega Diagnostics Limited, Investment in Genesis Diagnostics Limited, Investment in Cambridge Nutritional Sciences Limited, Investment in Bealaw (692) Limited and Investment in Bealaw (693) Limited.

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company's lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The company's preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.